Quick Facts

• Main Use: Reduction of the risk of blood clots.
• Therapeutic Domains: Deep venous thrombosis (DVT) and pulmonary embolism (PE).
• Also Approved For: Prophylaxis of blood clots following certain procedures.

What Prevas Treats: Main Uses and Benefits

Prevas is a prescription medication approved for specific therapeutic indications related to managing blood coagulation. Its primary use is to reduce the risk of developing harmful blood clots.

The medication is indicated for adult patients for the management of deep venous thrombosis (DVT), a condition involving clots in a deep vein, and pulmonary embolism (PE), which is a clot in the lungs. Furthermore, Prevas may be utilized to prevent a recurrence of DVT and PE in patients who have received previous treatment for these conditions.

Another approved domain of use is for the prophylaxis, or prevention, of DVT and PE in adult patients who have recently undergone hip replacement surgery. The goal of this therapy is to maintain established therapeutic protocols for preventing thromboembolic events.

Official Eligibility Profile for Prevas

The eligibility for Prevas (Omeprazole) is defined by regulatory bodies based on age, physiological state, and existing medical conditions or co-administered medications. All uses are subject to formal regulatory constraints.

During pregnancy, use is not universally recommended unless the benefit is judged to outweigh potential risk. For lactation, Omeprazole is excreted in breast milk, and the decision to use the medicine requires careful consideration of the infant's exposure.

Interactions with other medicines and products

The interaction profile for Prevas (omeprazole) is governed by two principal mechanisms: its inhibition of the CYP2C19 enzyme and its effect on increasing gastric pH (reducing acidity), both of which can alter the exposure of co-administered medicines.

Interaction Scope

Interaction-related restrictions and formal statements

Co-administration with the antiretrovirals Rilpivirine and Nelfinavir is formally contraindicated due to the risk of significant loss of exposure to these medicines. The antiplatelet activity of Clopidogrel is diminished when co-administered due to reduced exposure to its active metabolite, a restriction noted in official labeling in some regions. Omeprazole increases the systemic exposure of Digoxin and Tacrolimus, and can increase the plasma concentrations of Diazepam and Phenytoin due to reduced metabolism. Conversely, the herbal product St. John's Wort is associated with decreased omeprazole plasma concentrations. Substances requiring an acidic gastric environment for absorption, such as Ketoconazole, will have their exposure reduced.

Prevas is a nitrogen-containing bisphosphonate that rapidly targets the osteoclast surface, where it is taken up by the cell. Its core pharmacodynamic mechanism involves acting as an inhibitor of the mevalonate pathway enzyme, farnesyl diphosphate synthase (FPPS). The inhibition of FPPS prevents the synthesis of isoprenoid lipids, such as farnesyl diphosphate and geranylgeranyl diphosphate. These isoprenoid lipids are required for the post-translational modification and activation of signaling GTPases essential for osteoclast function, motility, and the formation of the ruffled border. Blocking this cascade leads to osteoclast inactivation and cellular apoptosis, thereby causing a reduction in the resorption and degradation of the underlying bone matrix. This cellular modulation affects the overall composition and structure of the skeletal matrix.

Prevas (Omeprazole) is administered primarily via the oral route using delayed-release capsules or tablets, but an intravenous injection is also an approved route reserved for patients unable to take the medicine orally.

The medication is utilized in a standard once-daily dosing regimen for most adult conditions, with common doses ranging from 20 mg to 40 mg. However, for pathological hypersecretory conditions like Zollinger-Ellison Syndrome, the starting dose is 60 mg, and total daily doses exceeding 80 mg are divided and taken across the day.

Oral administration requires strict adherence to timing and preparation: the medicine is taken before eating, preferably in the morning. To maintain the integrity of the gastro-resistant formulation, the delayed-release capsule or tablet must be swallowed whole and must not be crushed, chewed, or cut. If a dose is missed, it is typically taken as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped.

Administration rules for specific groups detail that pediatric dosing is weight-based. While no adjustments are required for older adults or those with renal impairment, a lower daily dose may be necessary for patients with severe hepatic impairment.

Research evidence / Overview of studies for Prevas

Evidence for use in Chronic Pain Management

The investigational drug, Prevas, was evaluated in research involving people with long-term, non-cancer pain, such as chronic low back pain. Researchers examined this in both short-term and intermediate-term randomized controlled trials (RCTs). These studies included adults with moderate to severe baseline pain and measured outcomes related to physical discomfort and daily functioning. Studies monitored patterns observed over follow-up periods that typically lasted between 4 weeks and 6 months. The overall evidence quality was broadly described as moderate.

Evidence is limited regarding the experience in this context beyond six months, as long-term effects are not fully established. Follow-up durations were limited in many trials, and sample sizes were modest in some RCTs. These findings describe group patterns, not personal outcomes.

Evidence for use in Neuropathic Pain

Research was evaluated in specific types of neuropathic pain, primarily painful diabetic neuropathy (PDN) and post-herpetic neuralgia (PHN). The research consisted of short-term RCTs and systematic reviews which focused on outcomes related to physical discomfort, such as average daily pain scores and sleep interference. The available evidence is limited and has been broadly described as low certainty, with follow-up durations typically restricted to a few weeks.

What is still uncertain about Prevas

Certainty remains low for long-term outcomes and for use in many special populations. Comparative evidence is lacking to directly understand how the observed patterns relate to other established therapies. Because follow-up durations were limited, the studies provide limited insight into the persistence of any observed changes over time.

Key Studies & References Post-Marketing Surveillance in 2025: Evolving Strategies for Real-World Safety Monitoring (Supports context for limitations in long-term and special populations data)

Common questions about Prevas (FAQ)

Q: What is Prevas used to treat?

According to the official product information, Prevas is indicated for the treatment of mild to moderate hypertension (high blood pressure). It is also approved for use as an adjunctive therapy in patients with stable angina pectoris (chest pain due to reduced blood flow to the heart).

Q: How long does Prevas take to start working?

Studies and official information indicate that the peak plasma concentration—the highest level of the medicine in the blood—is typically reached between 1 and 3 hours after administration. This indicates when the substance is highly concentrated in the body, although the full clinical effect on blood pressure requires consistent use over time and may vary by individual.

Q: Does Prevas interact with commonly used non-prescription pain relievers like Ibuprofen?

Regulatory documents state that caution is advised when Prevas is used concurrently with non-steroidal anti-inflammatory drugs (NSAIDs), such as Ibuprofen. NSAIDs may reduce the blood pressure-lowering effect of Prevas. The potential for this interaction is noted in the official product information.

Q: Is it safe to drink alcohol while taking Prevas?

Official product information notes that alcohol may potentiate the action of Prevas, specifically by increasing the likelihood of orthostatic hypotension (a form of low blood pressure that occurs upon standing up). The product information suggests caution regarding alcohol intake, noting that it may enhance the drug's effects and potentially increase the risk of adverse reactions.

Q: What should I do if I miss a dose of Prevas?

Official instructions advise against taking a double dose to compensate for a missed one. Instead, the patient information typically directs users to resume the dosing schedule by taking the next dose at the scheduled time.

Q: What is the mechanism of action of Prevas?

Prevas is classified as a Calcium Channel Blocker. Regulatory documents explain that it works by inhibiting the influx of calcium ions into vascular smooth muscle cells and cardiac muscle. This action causes vasodilation (widening of blood vessels), which in turn reduces blood pressure and decreases the workload on the heart.

Q: Can Prevas be crushed or split to make it easier to swallow?

Official information regarding the preparation of the tablets states that the tablets are typically film-coated and should be swallowed whole with a glass of liquid. Official product information does not explicitly permit crushing or splitting the tablets. This caution is often related to maintaining the intended controlled release or stability of the medication.

How to Store and Dispose of Prevas (Omeprazole)

Official regulatory labeling dictates strict conditions for storing and discarding Prevas to maintain its stability and effectiveness.

Storage Requirements

Oral forms must be stored at controlled room temperature, generally not above 30 C (86 F), and must be protected from light and moisture. The medication should be kept in the original container and, if in a bottle, must be kept tightly closed.

Intravenous (IV) powder must also be stored below 25 C and protected from light. The reconstituted IV solution has a limited stability period of 6 to 12 hours at ambient temperature.

All forms must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Prevas must be disposed of in accordance with local requirements for pharmaceutical waste. Do not throw the medication into general household trash or wastewater unless specifically instructed by an authorized governmental agency.